Humana (HUM) Earnings Date & Reports
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more
HUM is expected to report earnings to fall 29.87% to $7.23 per share on July 29
Humana Inc. (HUM) Q1 2026 Earnings Recap: Adjusted EPS Beats Estimates
Key Takeaways
- Humana reported Q1 2026 adjusted diluted EPS of $10.31, beating consensus estimates around $10.20 and representing the high end of company guidance.
- Revenue reached $39.65 billion, up 23.5% year-over-year and topping expectations of about $39.47 billion.
- Insurance segment benefit ratio (percentage of premiums used for medical costs) improved to 89.4%, better than the company's guidance of just under 90%.
- Affirmed full-year 2026 adjusted EPS guidance of at least $9.00 but trimmed GAAP EPS outlook to at least $8.36 from $8.89.
- Reaffirmed approximately 25% growth in individual Medicare Advantage (MA) membership for FY 2026.
- CenterWell Senior Primary Care saw sequential patient growth of over 22%, including contributions from the MaxHealth acquisition.
Earnings Context and Why It Matters
Humana Inc., a leading health insurer focused on Medicare Advantage (MA) plans, government-sponsored programs, and primary care services, released its first quarter 2026 results on April 29, 2026. This report is critical amid ongoing pressures in the MA market, including regulatory changes, rising medical costs, and Star Ratings impacts on reimbursements. Investors closely watch membership trends, benefit ratios, and guidance updates, as Humana derives over 80% of revenue from MA. Strong execution here signals resilience in a competitive landscape dominated by peers like UnitedHealth, influencing sector valuations and policy debates on MA sustainability.
Humana posted consolidated revenue of $39.65 billion for the quarter ended March 31, 2026, a 23.5% increase from Q1 2025, exceeding Wall Street's consensus of $39.47 billion. GAAP diluted EPS came in at $9.83, down from $10.30 in the prior year, while adjusted (non-GAAP) EPS of $10.31 topped estimates near $10.20 but declined from $11.58 year-over-year.
In the Insurance segment, pretax income was $1.435 billion on a GAAP basis (adjusted $1.439 billion), with the benefit ratio at 89.4%, favorably ahead of guidance. The CenterWell segment contributed to overall results, with sequential growth in senior primary care patients exceeding 22%. Consolidated pretax income totaled $1.595 billion (GAAP) and $1.670 billion (adjusted). Operating cost ratio improved to 10.2% (GAAP) from 10.6% a year ago.
Guidance updates included affirmed FY 2026 adjusted EPS of at least $9.00 and Insurance benefit ratio of 92.75% (±25 basis points), but GAAP EPS was lowered to at least $8.36 due to adjustments like value creation initiatives.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Despite the earnings beat, HUM shares declined around 3% to 5% in post-release trading on April 29, 2026, settling lower amid broader market caution. Investors appeared focused on the GAAP guidance reduction and year-over-year EPS drop, overshadowing revenue strength and affirmed adjusted outlook. Sentiment reflects concerns over MA margins and Star Ratings headwinds, though membership growth projections provided some offset.
Forward Outlook and Key Factors to Monitor
Humana's affirmed FY 2026 guidance points to adjusted EPS of at least $9.00, supported by robust individual MA membership expansion of about 25% from 2025 levels. This growth stems from enhanced sales, retention via customer-focused benefits, and service improvements.
Investors should track the Insurance segment benefit ratio, held at 92.75% (±25 bps), as medical cost trends and utilization patterns evolve. Progress in CenterWell, including senior primary care (up over 22% sequentially) and pharmacy partnerships, could drive diversification beyond MA.
State-based contract growth, adding ~50,000 members in Q1, offers upside in Medicaid. Regulatory risks like CMS rate notices for 2027 and Star Ratings for Bonus Year 2026 remain pivotal. Leadership transitions in Insurance, with Aaron Martin taking over, warrant attention for execution continuity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a company offers health insurance coverage and related services
Industry ManagedHealthCare